Table 1.
Demographic and Clinical Characteristics of the Patients
| AS03A adjuvanted H1N1v vaccine(3.75 μg HA) |
Nonadjuvanted H1N1v vaccine(15 μg HA) |
With HAART | Without HAART | All | |||||
| Characteristic | WithHAART | Without HAART | All | With HAART | Without HAART | All | |||
| No. of patients | 120 | 35 | 155 | 117 | 34 | 151 | 237 | 69 | 306 |
| Female sex | 19 (16) | 4 (11) | 23 (15) | 25 (21) | 11 (32) | 36 (24) | 44 (19) | 15 (22) | 59 (19) |
| Age, median years (IQR) | 47.3 (41.7–54.7) | 42.5 (33.2–50.1) | 46.5 (38.6–54.0) | 48.8 (44.2–54.7) | 39.0 (32.6–45.7) | 47.3 (40.2–53.6) | 47.7 (42.5–54.7) | 40.7 (33.2–48.6) | 46.9 (40.0–53.8) |
| CDC stage C | 38 (32) | 2 (6) | 40 (26) | 38 (33) | 1 (3) | 39 (26) | 76 (32) | 3 (4) | 79 (26) |
| Smoker | 45 (38) | 16 (46) | 61 (39) | 37 (32) | 13 (38) | 50 (33) | 82 (34) | 29 (42) | 111 (36) |
| HCV and/or HBV coinfection | 18 (15) | 5 (14) | 23 (15) | 14 (12) | 2 (6) | 16 (11) | 32 (14) | 7 (10) | 39 (13) |
| HBsAg positive | 8 (6.7) | 2 (5.7) | 10 (6.5) | 5 (4.3) | 0 (0) | 5 (3.3) | 13 (5.5) | 2 (2.9) | 15 (4.9) |
| Anti-HCV antibody positive | 10 (8.4) | 3 (8.6) | 13 (8.4) | 10 (8.5) | 2 (5.9) | 12 (7.9) | 20 (8.5) | 5 (7.2) | 25 (8.2) |
| Nadir CD4+ cell count, median cells/mm3 (IQR) | 190 (89–278) | 435 (336–542) | 240 (107–369) | 173 (86–253) | 451 (348–541) | 204 (95–371) | 177 (86–263) | 447 (348–541) | 229 (106–369) |
| Baseline CD4+ cell count median cells/mm3 (IQR) | 537 (383–763) | 503 (364–602) | 522 (378–752) | 560 (422–712) | 522 (451–635) | 551 (428–702) | 556 (407–736) | 507 (421–611) | 536 (412–706) |
| Baseline CD4+ cell count <200 cells/mm3 | 6 (5.0) | 0 (0) | 6 (3.9) | 3 (3.4) | 0 (0) | 3 (2.6) | 9 (3.8) | 0 (0) | 9 (3.0) |
| Baseline CD4+ cell count 200–349 cells/mm3 | 21 (17.5) | 7 (20) | 28 (18.1) | 14 (12.1) | 1 (2.9) | 15 (10.0) | 35 (14.8) | 8 (11.8) | 43 (14.1) |
| Baseline CD4+ cell count 350–499 cells/mm3 | 25 (20.8) | 10 (28.6) | 35 (22.6) | 28 (24.1) | 13 (38.2) | 41 (27.3) | 53 (22.5) | 23 (33.3) | 76 (24.9) |
| Baseline CD4+ cell count ≥500 cells/mm3 | 68 (56.7) | 18 (51.4) | 86 (55.5) | 71 (61.2) | 20 (58.8) | 91 (60.7) | 139 (58.9) | 38 (55.1) | 177 (58) |
| HIV-1 viral load, median copies/mL (IQR) | 20 (20–40) | 13372 (1524–46081) | 40 (20–50) | 20 (20–40) | 8306 (3850–29048) | 40 (20–61) | 20 (20–40) | 9127 (3183–38200) | 40 (20–50) |
| HIV-1 viral load <50 copies/mL | 116 (97) | 3 (9) | 119 (77) | 112 (96) | 0 (0) | 112 (74) | 228 (96) | 3 (4) | 231 (76) |
| Received 2009 seasonal influenza vaccine | 32 (27) | 7 (20) | 39 (33) | 33 (28) | 6 (18) | 39 (26) | 65 (27) | 13 (19) | 78 (26) |
| Received 2009 pneumococcal vaccine | 36 (30) | 6 (17) | 42 (27) | 31 (27) | 8 (24) | 39 (26) | 67 (28) | 14 (20) | 81 (27) |
NOTE. Data are no. (%) of patients, unless otherwise indicated. CDC, Centers for Disease Control and Prevention; HA, hemagglutinin; HAART, highly active antiretroviral therapy; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatits C virus; IQR, interquartile range.